Quality control and safety assessment of BCG vaccines in the post-genomic era
Open Access
- 4 May 2014
- journal article
- review article
- Published by Informa UK Limited in Biotechnology & Biotechnological Equipment
- Vol. 28 (3), 387-391
- https://doi.org/10.1080/13102818.2014.927200
Abstract
A hundred and five years ago, Albert Calmette and Camille Guérin began a daunting task, which is unmatched even today, that led to the most widely used vaccine in human history. Despite a century of scientific advances, BCG (an acronym for Bacillus Calmette–Guérin) remains the only vaccine for prevention of tuberculosis. Due to the fact that the use of BCG vaccines will continue, either as a stand-alone or as a prime vaccine in prime-boost immunization strategies, the World Health Organization (WHO) has underlined the necessity for further work toward better characterization, evaluation and quality control of the BCG vaccine, taking into account recent advances in genetics and molecular biology. The potential benefit of such improved characterization could be addressed to better and easier differentiation between sub-strains used by different manufacturers. It may help to ensure consistency of production in terms of genetic stability and it may also help the clinical evaluation of new antituberculosis vaccines. Last but not least, the state-of-the-art technologies could facilitate the quality control performed by the manufacturers and by National Control Authorities as well.Keywords
This publication has 15 references indexed in Scilit:
- Report of an international collaborative study to evaluate the suitability of multiplex PCR as an identity assay for different sub-strains of BCG vaccineVaccine, 2010
- Development of a Murine Mycobacterial Growth Inhibition Assay for Evaluating Vaccines againstMycobacterium tuberculosisClinical and Vaccine Immunology, 2009
- Development and validation of an ATP method for rapid estimation of viable units in lyophilised BCG Danish 1331 vaccineBiologicals, 2008
- Report of an international collaborative study to establish the suitability of using modified ATP assay for viable count of BCG vaccineVaccine, 2008
- Genome plasticity of BCG and impact on vaccine efficacyProceedings of the National Academy of Sciences, 2007
- WHO discussion on the improvement of the quality control of BCG vaccines: Pasteur Institute, Paris, France, 7 June 2005Vaccine, 2006
- Mycobacterium bovis BCG Substrains Confer Different Levels of Protection against Mycobacterium tuberculosis Infection in a BALB/c Model of Progressive Pulmonary TuberculosisInfection and Immunity, 2006
- Genetic Composition of Mycobacterium bovis BCG Substrain SofiaJournal of Clinical Microbiology, 2003
- Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequenceNature, 1998
- Firefly luciferase assay of adenosine triphosphate as a tool of quantitation of the viability of BCG vaccinesBiologicals, 1995